The Influence of FTO, FABP2, LEP, LEPR, and MC4R Genes on Obesity Parameters in Physically Active Caucasian Men

Maculewicz, Ewelina; Leońska-Duniec, Agata; Mastalerz, Andrzej; Szarska, Ewa; Garbacz, Aleksandra; Lepionka, Tomasz; Łakomy, Roman; Anyżewska, Anna; Bertrandt, Jerzy

doi:10.3390/ijerph19106030

Cited by 2 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inclusion criteria: Healthy participants aged between 40 and 60 years; BMI of 25 or greater and no more than a 3% change in body mass within the last three months; Presence of at least one minor allele in any of the following genetic polymorphisms: FTO (rs9939609; T > A), LEP (rs2167270; G > A), LEPR (rs1137101; A > G; Gln223Arg), and MC4R (rs17782313; T > C) [ 38 ]. …”

Section: Methodsmentioning

confidence: 99%

“…Presence of at least one minor allele in any of the following genetic polymorphisms: FTO (rs9939609; T > A), LEP (rs2167270; G > A), LEPR (rs1137101; A > G; Gln223Arg), and MC4R (rs17782313; T > C) [ 38 ].…”

Section: Methodsmentioning

confidence: 99%

“…These supplements are known to influence weight management through mechanisms like appetite suppression and enhanced satiety [ 37 ]. Simultaneously, the selected genetic polymorphisms are implicated in obesity predominantly due to their influence on eating behaviors, specifically predisposition to overeating [ 38 ]. By scientifically correlating these genetic markers with the physiological effects of dietary fibers, our research aims to establish a more nuanced understanding of obesity management, tailored to individual genetic profiles.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial

Pokushalov,

Ponomarenko,

Garcia

et al. 2024

Nutrients

View full text Add to dashboard Cite

This study aimed to determine the impact of a fiber supplement on body weight and composition in individuals with obesity with specific genetic polymorphisms. It involved 112 adults with obesity, each with at least one minor allele in the FTO, LEP, LEPR, or MC4R polymorphism. Participants were randomized to receive either a fiber supplement (glucomannan, inulin, and psyllium) or a placebo for 180 days. The experimental group showed significant reductions in body weight (treatment difference: −4.9%; 95% CI: −6.9% to −2.9%; p < 0.01) and BMI (treatment difference: −1.4 kg/m2; 95% CI: −1.7 to −1.2; p < 0.01) compared to placebo. Further significant decreases in fat mass (treatment difference: −13.0%; 95% CI: −14.4 to −11.7; p < 0.01) and visceral fat rating (treatment difference: −1.3; 95% CI: −1.6 to −1.0; p < 0.01) were noted. Homozygous minor allele carriers experienced greater decreases in body weight (treatment difference: −3.2%; 95% CI: −4.9% to −1.6%; p < 0.01) and BMI (treatment difference: −1.2 kg/m2; 95% CI: −2.0 to −0.4; p < 0.01) compared to heterozygous allele carriers. These carriers also had a more significant reduction in fat mass (treatment difference: −9.8%; 95% CI: −10.6 to −9.1; p < 0.01) and visceral fat rating (treatment difference: −0.9; 95% CI: −1.3 to −0.5; p < 0.01). A high incidence of gastrointestinal events was reported in the experimental group (74.6%), unlike the placebo group, which reported no side effects. Dietary supplementation with glucomannan, inulin, and psyllium effectively promotes weight loss and improves body composition in individuals with obesity, particularly those with specific genetic polymorphisms.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial

Pokushalov,

Ponomarenko,

Garcia

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

“…GWAS studies found a strong association between common variants in monogenic-obesity-causing genes and the development of common obesity. For example, the SNP rs17782313, located 188 kb downstream of the MC4R gene, was found to be significantly associated with a higher BMI, higher fat mass, and elevated risk of common obesity in various populations with different genetic backgrounds, including Caucasians, Mexican, Chinese, and Iranian [206][207][208][209][210][211][212][213][214]. The SNP is suggestively involved in MC4R expression and translation regulation, and consequently affects food intake and nutrient preference [215,216].…”

mentioning

confidence: 99%

Adipose Tissue Hyperplasia and Hypertrophy in Common and Syndromic Obesity—The Case of BBS Obesity

Horwitz

Birk

2023

Nutrients

View full text Add to dashboard Cite

Obesity is a metabolic state generated by the expansion of adipose tissue. Adipose tissue expansion depends on the interplay between hyperplasia and hypertrophy, and is mainly regulated by a complex interaction between genetics and excess energy intake. However, the genetic regulation of adipose tissue expansion is yet to be fully understood. Obesity can be divided into common multifactorial/polygenic obesity and monogenic obesity, non-syndromic and syndromic. Several genes related to obesity were found through studies of monogenic non-syndromic obesity models. However, syndromic obesity, characterized by additional features other than obesity, suggesting a more global role of the mutant genes related to the syndrome and, thus, an additional peripheral influence on the development of obesity, were hardly studied to date in this regard. This review summarizes present knowledge regarding the hyperplasia and hypertrophy of adipocytes in common obesity. Additionally, we highlight the scarce research on syndromic obesity as a model for studying adipocyte hyperplasia and hypertrophy, focusing on Bardet–Biedl syndrome (BBS). BBS obesity involves central and peripheral mechanisms, with molecular and mechanistic alternation in adipocyte hyperplasia and hypertrophy. Thus, we argue that using syndromic obesity models, such as BBS, can further advance our knowledge regarding peripheral adipocyte regulation in obesity.

show abstract

The Influence of FTO, FABP2, LEP, LEPR, and MC4R Genes on Obesity Parameters in Physically Active Caucasian Men

Cited by 2 publications

References 39 publications

The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial

The Impact of Glucomannan, Inulin, and Psyllium Supplementation (SolowaysTM) on Weight Loss in Adults with FTO, LEP, LEPR, and MC4R Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial

Adipose Tissue Hyperplasia and Hypertrophy in Common and Syndromic Obesity—The Case of BBS Obesity

Contact Info

Product

Resources

About